These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9116275)

  • 1. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
    Najean Y; Rain JD
    Blood; 1997 Apr; 89(7):2319-27. PubMed ID: 9116275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
    Najean Y; Rain JD; Goguel A; Grange MJ; Vigneron N; Dupuy E; Mougeot-Martin M
    Ann Med Interne (Paris); 1998 Mar; 149(2):87-93. PubMed ID: 11490530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 32P-therapy in polycythemia vera.
    Meuret G; Hoffmann G; Gmelin R
    Klin Wochenschr; 1975 Jun; 53(11):519-21. PubMed ID: 807769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A; Silverstein MN
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
    Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
    [No Abstract]   [Full Text] [Related]  

  • 8. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available?
    Brandt L; Anderson H
    Eur J Haematol; 1995 Jan; 54(1):21-6. PubMed ID: 7859872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.
    Najean Y; Rain JD
    Blood; 1997 Nov; 90(9):3370-7. PubMed ID: 9345019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy of 32P-induced remission in polycythemia vera. A clinical trial of chlorambucil and hydroxy-urea in 109 cases.
    Najean Y; Dresch C; Rain JD
    Nouv Rev Fr Hematol (1978); 1978 Nov; 20(3):377-85. PubMed ID: 112580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of 32 phosphorus (32P) in the treatment of polycythemia vera.
    Parmentier C; Gardet P
    Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):189-92. PubMed ID: 8036140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980].
    Najean Y; Rain JD; Toubert ME
    Presse Med; 1993 Dec; 22(39):1951-6. PubMed ID: 8121914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
    Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
    Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hydroxyurea--is it a harmless drug in Vaquez disease?]].
    Rain JD
    Pathol Biol (Paris); 2001 Mar; 49(2):158-63. PubMed ID: 11317962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
    Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
    J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can pegylated interferon improve the outcome of polycythemia vera patients?
    Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
    J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Boivin P
    Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.